The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4

NCT07241169 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Stargardt

Interventions

DRUG: ZVS106e

Sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University

Collaborators

[object Object]